Korro Bio (KRRO) investor relations material

Executive summary

• Advanced lead program KRRO-121 toward regulatory filing in H2 2026 for hyperammonemia in UCDs and HE, with strong preclinical data and potential for first-in-class therapy.

• Achieved >90% in vivo RNA editing in GalNAc-conjugated AATD program, with development candidate announcement expected in Q2 2026.

• No product sales to date; operations funded primarily through equity offerings, including an $85M private placement and $5.1M ATM offering in Q1 2026.

• Workforce reductions and program reprioritization implemented in 2025 to extend cash runway and focus on core programs.

• Advanced preclinical R&D for AMPKY1 (longevity medicine) and TDP-43 (ALS), and participated in major healthcare conferences.

Financial highlights

• Cash, cash equivalents, and marketable securities totaled $157.1M as of March 31, 2026, up from $85.2M at December 31, 2025.

• Net loss of $19.6M for Q1 2026, improved from $23.4M in Q1 2025, driven by lower R&D and G&A expenses.

• Research and development expenses decreased to $12.9M from $19.7M year-over-year, mainly due to lower KRRO-110 and personnel costs.

• General and administrative expenses were $7.5M, down from $7.8M year-over-year.

• No collaboration revenue recognized in Q1 2026 due to a 12-month pause in the Novo Nordisk partnership.

Outlook and guidance

• Cash runway expected to fund operations into the second half of 2028, with continued focus on advancing KRRO-121 and AATD programs.

• Regulatory filing for KRRO-121 first-in-human trial anticipated in H2 2026; AATD development candidate nomination expected in Q2 2026.

• Third GalNAc-conjugated program candidate nomination expected in H2 2026.

• No material collaboration revenue expected during the Novo Nordisk hold period.